drug · small molecule
apixaban
pre_registrationupdated 6mo agoby Taho Pharmaceuticals Ltd🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- drugapixaban ER5 co-mentions · 2 sources
- drugapixaban ODT5 co-mentions · 2 sources
- tagOncology2 co-mentions · 1 sources
- tagHematology2 co-mentions · 1 sources
- tagAdCom2 co-mentions · 1 sources
- tag510(k) Clearance2 co-mentions · 1 sources
- tagDiagnostics Company2 co-mentions · 1 sources
- companyMedical University of Gdansk1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 14 investigational indications.
targets
Coagulation factor X
all catalysts(0)
nothing on the calendar yet
Trials studying apixaban
- phase3Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
- phase3Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
- phase2Vortosiran in Atrial Fibrillation
- phase3REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
- phase1Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant
- N/ADEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
- phase2Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
- phase3A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
News(10)
- Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concernsMerck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.biospace · 21h ago
- Blackstone bets $1.5B on Pfizer’s obesity drugThe deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.biopharma_dive · 6d ago
- Bristol Myers research chief to depart in ‘evolution’ of company’s structureRobert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.biopharma_dive · 6d ago
- Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera assetWith 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.biospace · 6d ago
- BMS R&D head to depart amid restructureBristol Myers Squibb is combining all research and development efforts under one leader as pressure rises to replenish its pipeline.biospace · 6d ago
- Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rivalBayer’s Sunharbo has secured the first FDA approval of its class, establishing a regulatory pathway for other factor XIa inhibitors, such as Bristol Myers Squibb and Johnson and Johnson’s milvexian.biospace · 8d ago
- Pfizer flat in Q3 despite 32% growth for new and acquired productsSales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.biospace · 15d ago
- BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beatIn addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…biospace · 20d ago
- J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutbackJohnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio bu…biospace · 1mo ago
- BMS’ Phase 3 win for lung drug clouded by high-dose missA low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awa…biospace · 1mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that